Abstract:: PARPi have been explored and applied in the treatment of various cancers with remarkable efficacy, especially BRCA1/2 mutated ovarian, breast, prostate, and pancreatic cancers. However, PARPi renders inevitable drug resistance and showed high toxicity because of PARP-Trapping with long-term clinic tracking. To overcome the drug resistance and the high toxicity of PARPi, many novel methods have been developed including PROTACs. Being an event-driven technology, PROTACs needs a high affinity, low toxicity warhead with no steric hinderance in binding process. Veliparib shows the lowest PARP-Trapping effect but could hardly to be the warhead of PROTACs because of the strong steric hinderance. Other PARP1 inhibitors showed less steric hinderance but owns high PARP-Trapping effect. Thus, the development of novel warhead with high PARP1 affinity, low PARP1-Trapping, and no steric hinderance would be valuable. In this work, we reserved benzimidazole as the motif to reserve the low PARP1-Trapping effect and substituted the pyrrole by aromatic ring to avoiding the steric hindrance in PARP1 binding cave. Thus, a series of benzimidazole derivates were designed and synthesized, and some biological activities in vitro were evaluated including the inhibition for PARP1 enzyme and the PARP-Trapping effect using MDA-MB-436 cell line. Results showed that the compound 19A10 has higher PARP1 affinity( IC 50 = 4.62 nM)) and similar low PARP-Trapping effect compared with Veliparib( IC 50 (MDA-MB-436) >100 μM). Docking study showed that the compound 19A10 could avoiding the steric hindrance which was much better than Veliparib. So, the compound 19A10 could potentially be a perfect warhead for PARP1 degraders. Besides, because of the depletion of the PARP1 and the decreasing of the binding capability, we suppose that the PROTACs using 19A10 as the warhead would be no-PARP-Trapping effect. Furthermore, QSAR study showed that to develop novel compounds with high PARP1 binding affinity and low PARP-Trapping, we can choose the skeleton with substituent R 1 =H, R 2 =piperiazine, and R 3 with large tPSA. And, if we want to develop the compounds with high PARP1 binding affinity and high PARP-Trapping which can possibly improve the lethality against tumor cells, we can choose the skeleton with substituent R 1 =F, R 2 =3-methy-piperiazine, and R 3 with large tPSA.

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Identification of Probe-Quality Degraders for Poly(ADP-ribose) Polymerase-1 (PARP-1)

High Affinity and Low PARP-Trapping Benzimidazole Derivatives as a Potential Warhead for PARP1 Degraders

Synthesis and biological evaluation of a tumor-selective degrader of PARP1

Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer

KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway

The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer

The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction

Identification of [1,2,4]Triazolo[4,3- a ]pyrazine PARP1 inhibitors with overcome acquired resistance activities

The discovery of a potent PARP1 inhibitor Senaparib

Synthesis and in Vitro Biological Evaluation of 3-Ethyl-1,5-naphthyridin-2(1h)-one Derivatives As Potent PARP-1 Selective Inhibitors and PARP-1 DNA Trappers

Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening

Development of Poly(adp-Ribose) Polymerase Inhibitors for Cancertherapy

Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305

Progress in the research of PARP inhibitors and their mechanisms of action

DePARylation is critical for S phase progression and cell survival

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (Adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Enhancing PARP Inhibitor Efficacy Using Reduction-Responsive Nanoparticles Encapsulating NADP+